Protalix Biotherapeutics Inc
AMEX:PLX
Protalix Biotherapeutics Inc
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 193 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 193 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.
Revenues: Total revenues for the first 9 months of 2025 were $43.6 million, up 24% year-on-year; Q3 revenues were $17.9 million, down 1% year-on-year.
Net Income: Q3 2025 net income was $2.4 million, down from $3.2 million in Q3 2024, while the company posted a net loss of $1.1 million for the first 9 months of 2025.
Pipeline Progress: IND for Phase II trial of PRX-115 was filed and accepted; patient screening planned to start soon, with top-line results expected in Q3 2027.
Regulatory Update: Reexamination of the once-every-4-weeks Elfabrio regimen in Europe is underway, with a decision expected in Q1 2026.
Financial Position: Cash and equivalents of $29.4 million at quarter-end, expected to fund operations and clinical trials for at least 12 months.
R&D Investment: Research and development spending rose sharply due to PRX-115 Phase II trial preparations.
